ENZ
Price
$0.71
Change
+$0.01 (+1.43%)
Updated
Dec 18, 04:12 PM (EDT)
SIBN
Price
$13.55
Change
-$0.29 (-2.10%)
Updated
Dec 18, 04:31 PM (EDT)
75 days until earnings call
Ad is loading...

ENZ vs SIBN

Header iconENZ vs SIBN Comparison
Open Charts ENZ vs SIBNBanner chart's image
Enzo Biochem
Price$0.71
Change+$0.01 (+1.43%)
Volume$2.16K
CapitalizationN/A
SI-BONE
Price$13.55
Change-$0.29 (-2.10%)
Volume$3.36K
CapitalizationN/A
ENZ vs SIBN Comparison Chart
Loading...
ENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SIBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENZ vs. SIBN commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENZ is a Hold and SIBN is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ENZ: $0.70 vs. SIBN: $13.84)
Brand notoriety: ENZ and SIBN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ENZ: 1163% vs. SIBN: 65%
Market capitalization -- ENZ: $64.03M vs. SIBN: $672.23M
ENZ [@Medical Specialties] is valued at $64.03M. SIBN’s [@Medical Specialties] market capitalization is $672.23M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENZ’s FA Score shows that 2 FA rating(s) are green whileSIBN’s FA Score has 0 green FA rating(s).

  • ENZ’s FA Score: 2 green, 3 red.
  • SIBN’s FA Score: 0 green, 5 red.
According to our system of comparison, ENZ is a better buy in the long-term than SIBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENZ’s TA Score shows that 4 TA indicator(s) are bullish while SIBN’s TA Score has 5 bullish TA indicator(s).

  • ENZ’s TA Score: 4 bullish, 5 bearish.
  • SIBN’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, SIBN is a better buy in the short-term than ENZ.

Price Growth

ENZ (@Medical Specialties) experienced а -33.96% price change this week, while SIBN (@Medical Specialties) price change was -2.54% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.17%. For the same industry, the average monthly price growth was +1.60%, and the average quarterly price growth was -0.66%.

Reported Earning Dates

ENZ is expected to report earnings on Dec 16, 2024.

SIBN is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Medical Specialties (-4.17% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SIBN($672M) has a higher market cap than ENZ($64M). SIBN YTD gains are higher at: -34.064 vs. ENZ (-44.798). ENZ has higher annual earnings (EBITDA): -16.29M vs. SIBN (-34.45M). SIBN has more cash in the bank: 166M vs. ENZ (60.2M). ENZ has less debt than SIBN: ENZ (7.18M) vs SIBN (39M). SIBN has higher revenues than ENZ: SIBN (139M) vs ENZ (32.8M).
ENZSIBNENZ / SIBN
Capitalization64M672M10%
EBITDA-16.29M-34.45M47%
Gain YTD-44.798-34.064132%
P/E Ratio208.33N/A-
Revenue32.8M139M24%
Total Cash60.2M166M36%
Total Debt7.18M39M18%
FUNDAMENTALS RATINGS
ENZ vs SIBN: Fundamental Ratings
ENZ
SIBN
OUTLOOK RATING
1..100
5416
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
5958
P/E GROWTH RATING
1..100
13100
SEASONALITY SCORE
1..100
3085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENZ's Valuation (5) in the Biotechnology industry is somewhat better than the same rating for SIBN (42) in the Medical Specialties industry. This means that ENZ’s stock grew somewhat faster than SIBN’s over the last 12 months.

ENZ's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SIBN (100) in the Medical Specialties industry. This means that ENZ’s stock grew similarly to SIBN’s over the last 12 months.

SIBN's SMR Rating (94) in the Medical Specialties industry is in the same range as ENZ (96) in the Biotechnology industry. This means that SIBN’s stock grew similarly to ENZ’s over the last 12 months.

SIBN's Price Growth Rating (58) in the Medical Specialties industry is in the same range as ENZ (59) in the Biotechnology industry. This means that SIBN’s stock grew similarly to ENZ’s over the last 12 months.

ENZ's P/E Growth Rating (13) in the Biotechnology industry is significantly better than the same rating for SIBN (100) in the Medical Specialties industry. This means that ENZ’s stock grew significantly faster than SIBN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENZSIBN
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 23 days ago
69%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 6 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
ENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SIBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EADIX17.26N/A
N/A
Eaton Vance Global Equity Income A
SCECX14.35N/A
N/A
Steward Values Enhanced SmMidCapI
FEIKX77.78-0.42
-0.54%
Fidelity Equity-Income K
JESSX15.65-0.13
-0.82%
Janus Henderson Global Sust Eq S
RPMIX9.40-0.11
-1.16%
Royce Small-Cap Fund Instl

ENZ and

Correlation & Price change

A.I.dvisor tells us that ENZ and SINT have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENZ and SINT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENZ
1D Price
Change %
ENZ100%
-30.69%
SINT - ENZ
30%
Poorly correlated
+1.32%
QIPT - ENZ
29%
Poorly correlated
-15.15%
MASS - ENZ
26%
Poorly correlated
-5.58%
SIBN - ENZ
26%
Poorly correlated
+0.51%
TWST - ENZ
26%
Poorly correlated
-0.06%
More

SIBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SIBN has been loosely correlated with QTRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SIBN jumps, then QTRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SIBN
1D Price
Change %
SIBN100%
+0.51%
QTRX - SIBN
49%
Loosely correlated
-2.63%
KIDS - SIBN
41%
Loosely correlated
+0.81%
AORT - SIBN
41%
Loosely correlated
-0.21%
UTMD - SIBN
41%
Loosely correlated
-0.67%
NVRO - SIBN
38%
Loosely correlated
-2.41%
More